MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.826
EU - Europa 7.751
AS - Asia 7.097
SA - Sud America 885
OC - Oceania 521
AF - Africa 320
Continente sconosciuto - Info sul continente non disponibili 11
Totale 33.411
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.289
GB - Regno Unito 2.926
CN - Cina 1.572
SG - Singapore 1.487
IT - Italia 1.012
HK - Hong Kong 823
DE - Germania 795
BR - Brasile 670
SE - Svezia 628
PH - Filippine 532
AU - Australia 478
TR - Turchia 443
CA - Canada 411
VN - Vietnam 382
RU - Federazione Russa 336
FR - Francia 317
FI - Finlandia 293
IR - Iran 283
UA - Ucraina 275
IN - India 200
KR - Corea 179
PK - Pakistan 163
ID - Indonesia 149
IE - Irlanda 138
JP - Giappone 132
NL - Olanda 124
BG - Bulgaria 117
MY - Malesia 112
ES - Italia 104
PL - Polonia 104
GR - Grecia 97
ZA - Sudafrica 86
TW - Taiwan 85
IL - Israele 77
SA - Arabia Saudita 76
AR - Argentina 75
MA - Marocco 69
BE - Belgio 67
MX - Messico 67
AT - Austria 59
TH - Thailandia 51
LK - Sri Lanka 44
NP - Nepal 44
NZ - Nuova Zelanda 42
RO - Romania 42
NO - Norvegia 40
GE - Georgia 39
EC - Ecuador 36
JO - Giordania 36
IQ - Iraq 34
BD - Bangladesh 33
KE - Kenya 33
LT - Lituania 33
LV - Lettonia 32
CH - Svizzera 31
EE - Estonia 28
CO - Colombia 27
CZ - Repubblica Ceca 27
EG - Egitto 26
PT - Portogallo 23
HR - Croazia 22
CL - Cile 21
AE - Emirati Arabi Uniti 18
NG - Nigeria 18
HU - Ungheria 17
SI - Slovenia 17
SK - Slovacchia (Repubblica Slovacca) 17
BZ - Belize 14
PE - Perù 14
UG - Uganda 13
VE - Venezuela 13
OM - Oman 12
TN - Tunisia 12
UZ - Uzbekistan 11
PY - Paraguay 10
DK - Danimarca 9
MU - Mauritius 9
BH - Bahrain 8
CY - Cipro 8
DZ - Algeria 8
LB - Libano 8
BO - Bolivia 7
ET - Etiopia 7
KZ - Kazakistan 7
LY - Libia 7
PR - Porto Rico 7
UY - Uruguay 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DO - Repubblica Dominicana 6
MO - Macao, regione amministrativa speciale della Cina 6
MV - Maldive 6
PA - Panama 6
CR - Costa Rica 5
GY - Guiana 5
LU - Lussemburgo 5
MW - Malawi 5
PS - Palestinian Territory 5
QA - Qatar 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
Totale 33.323
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Southend 1.619
Ashburn 1.456
Santa Clara 1.286
Woodbridge 1.142
Singapore 932
Chandler 839
Houston 825
Hong Kong 737
Seattle 684
Wilmington 656
Cambridge 590
Jacksonville 505
Dearborn 428
Ann Arbor 404
Nyköping 401
Hefei 370
London 335
Beijing 324
Los Angeles 284
Chicago 254
Modena 227
New York 227
Frankfurt am Main 198
Redwood City 183
Helsinki 181
Munich 180
San Diego 178
Izmir 152
Ho Chi Minh City 125
Shanghai 118
Princeton 116
Sofia 113
Council Bluffs 109
Salt Lake City 108
Melbourne 104
Seoul 104
Hanoi 103
The Dalles 101
Eugene 96
Moscow 93
Dallas 92
Jakarta 79
Dublin 76
Milan 74
Manchester 69
Buffalo 66
Sydney 64
São Paulo 62
Istanbul 60
Tokyo 60
Bremen 59
Brisbane 59
Ottawa 59
Elk Grove Village 53
San Jose 52
Bologna 50
Columbus 50
Phoenix 48
Tampa 47
Warsaw 47
Falls Church 46
Taipei 46
Paris 45
Liverpool 43
Athens 42
Quezon City 38
Brussels 37
Des Moines 37
Fremont 37
Tehran 37
Casablanca 36
Johannesburg 35
Colombo 34
Dong Ket 34
Islamabad 34
Denver 33
Montreal 33
Kuala Lumpur 32
Cebu City 31
Karachi 31
Perth 31
Stockholm 31
Birmingham 30
Lahore 30
Manila 30
Riyadh 30
Toronto 30
Boston 29
Brooklyn 29
Atlanta 28
Davao City 28
Lancaster 28
Norwalk 28
Riga 28
Rome 28
Sterling 28
Vienna 27
Nanjing 26
Greenwich 25
Totale 21.213
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 6.686
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 631
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 589
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 583
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 481
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 458
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 450
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 432
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 388
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 362
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 358
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 357
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 355
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 345
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 342
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 336
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 330
Empathic attitudes among nursing students: a preliminary study 329
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 327
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 327
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 323
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 322
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 317
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 311
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 308
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 306
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 300
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 297
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 294
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 294
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 291
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 274
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 268
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 268
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 267
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 266
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 263
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 262
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 262
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 260
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 259
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 257
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 256
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 256
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 256
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 255
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 254
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 254
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 253
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 250
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 249
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 249
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 248
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 247
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 246
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 244
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 244
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 242
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 241
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 238
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 238
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 237
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 237
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 234
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 233
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 232
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 230
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 229
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 228
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 227
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 226
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 217
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 216
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 214
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 211
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 208
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 208
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 205
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 204
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 200
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 199
Twenty-years experience with de novo metastatic breast cancer 195
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 192
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 192
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 190
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 185
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 184
I tumori nelle provincie di Parma, Reggio Emilia, Modena 182
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 180
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 178
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 178
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 172
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 171
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 165
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 165
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 163
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 154
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 151
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 145
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 144
Totale 33.136
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.713
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.713
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.462 0 0 0 0 0 373 284 439 293 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/20265.401 658 424 690 1.193 1.679 757 0 0 0 0 0 0
Totale 33.823